Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

July 8 (Reuters) - Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to ...
FiercePharma

Respiratory patient groups see pharma's reputation as boosted in 2022, but decry pricing, access to lung meds

Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry's reputation in 2022 compared to the previous year. Nevertheless, they continue to identify ...
FiercePharma

AstraZeneca hit by marketing breaches across its respiratory drug range amid online slip-ups

AstraZeneca has been reprimanded by the U.K. drug marketing authority for a series of breaches of its code of conduct across its website for its respiratory franchise. A healthcare professional in the ...
Reuters

India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs

Feb 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and ...
Reuters

India's Lupin posts surge in quarterly profit on strong respiratory drugs demand

Nov 6 (Reuters) - Indian drugmaker Lupin (LUPN.NS), opens new tab posted a 73.3% jump in second-quarter profit on Thursday, driven by strong demand for its respiratory drugs. The firm, which produces ...
Hosted on MSN

Cipla focuses on respiratory therapies, specialty drugs and complex generics

As pricing pressure and commoditisation continue to weigh on traditional generics globally, pharma major Cipla is increasing its focus on differentiated respiratory products, chronic therapies, ...
Time

Many Asthma Patients Don’t Follow Their Medication Plans. Here’s How to Change That

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...